• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

2014-15,Profits down another 39%

Quote

Anonymous

Guest
This on top of the 28%profit loss the year before.With sh## products and 4500 more Actos lawsuits,this company is dead in the water,but will squeeze every last buck,any way it can,at anyone's expense,along the way!Integrity and scruples do not exist here anymore.Good luck to those that choose to ignore the signs!Hope the koo-aid is tasty!
 








That's not kool-ade they are slurping down. Just wait till the profit numbers come in on Contrave. 900 reps and can't beat the competitors even by taking a loss on the product. With all the lawsuits, Takeda can't survive much longer.
 




Anonymous said:
That's not kool-ade they are slurping down. Just wait till the profit numbers come in on Contrave. 900 reps and can't beat the competitors even by taking a loss on the product. With all the lawsuits, Takeda can't survive much longer.
Click to expand...

Not with the buffoons running it now!My thoughts and prayers go out to the many good people who will be affected by these jokers!
 








Top Bottom
Back
Quote